¶ Trouble for iproniazid, the remarkable new anti-depression drug introduced last year (TIME, Dec. 16), was sparked last week by the death of a San Francisco woman whose physician prescribed it. A coroner's jury ruled that her death (of hepatitis) was directly due to the drug, which is trade-named Marsilid by its maker, Hoffman-La Roche Inc. of Nutley. N.J. In January and February the drug house cut the recommended daily dosage for moderately depressed patients from 150 milligrams to a maximum of 50. It tried to notify most practicing U.S. physicians, but the information never reached the woman's doctor. Last week...
To continue reading:
or
Log-In
